Premium
Impact of 18 F‐FDG‐PET in decision making for liver metastectomy of colorectal cancer
Author(s) -
McLeish Andrew R.,
Lee Sze Ting,
Byrne Amanda J.,
Scott Andrew M.
Publication year - 2011
Publication title -
anz journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.426
H-Index - 70
eISSN - 1445-2197
pISSN - 1445-1433
DOI - 10.1111/j.1445-2197.2010.05601.x
Subject(s) - medicine , colorectal cancer , positron emission tomography , radiology , fluorodeoxyglucose , cancer , demographics , nuclear medicine , demography , sociology
Background: The ability of 18 F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) to impact on management of patients with recurrent colorectal cancer is high. However, direct impact of FDG‐PET on surgical management of patients with potentially resectable hepatic metastases is limited. Methods: FDG‐PET scans of patients with colorectal cancer at Austin Hospital in a 2‐year period were retrospectively evaluated. Data were collected on patient demographics, scan indication and sites of disease pre‐ and post‐PET. Results of standard imaging tests and FDG‐PET scans were analysed. The potential impact of FDG‐PET on proposed surgical management plans was assessed by an experienced surgeon. Results: There were 585 FDG‐PET scans performed on 470 patients (309M : 161F, mean age 61.9 years) with colorectal cancer. Hepatic metastases were identified on standard imaging in 232 (39.7%) patients, and FDG‐PET confirmed hepatic metastasis in 203 cases, including 22 cases with new lesions, and clarified presence of disease in 34/37 (92%) cases with equivocal standard imaging. In 54 patients, FDG‐PET was performed for disease assessment before hepatic resection. FDG‐PET had substantial management plan impact in 36/54 (66.7%) patients. Conclusions: FDG‐PET can profoundly impact on the management plan of patients with colorectal cancer who may be suitable for hepatic metastectomy.